Unknown

Dataset Information

Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy.


ABSTRACT: The use of dendritic cells (DCs) to generate effective anti-tumor T cell immunity has garnered much attention over the last thirty-plus years. Despite this, limited clinical benefit has been demonstrated thus far. There has been a revival of interest in DC-based treatment strategies following the remarkable patient responses observed with novel checkpoint blockade therapies, due to the potential for synergistic treatment. Cross-presenting DCs are recognized for their ability to prime CD8+ T cell responses to directly induce tumor death. Consequently, they are an attractive target for next-generation DC-based strategies. In this review, we define the universal classification system for cross-presenting DCs, and the vital role of this subset in mediating anti-tumor immunity. Furthermore, we

SUBMITTER: Audsley KM 

PROVIDER: S-EPMC7140519 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature